This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Cooper Companies (COO) Q3 Earnings Match Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 0% and 3.31%, respectively, for the quarter ended July 2023. Do the numbers hold clues to what lies ahead for the stock?
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
by Zacks Equity Research
BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.
Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sientra (SIEN) delivered earnings and revenue surprises of 3.41% and 7.48%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 25% and 7.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 5.68% and 2.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BioSig (BSGM) Inks New Deal to Advance AI in Electrophysiology
by Zacks Equity Research
The foundation of BioSig's (BSGM) AI medical device platform is set to be built upon integrated healthcare datasets.
The Zacks Analyst Blog Highlights ShockWave Medical, CheckCap and Biosig Technologies
by Zacks Equity Research
ShockWave Medical, CheckCap and Biosig Technologies are part of The Zacks top Analyst Blog.
3 Medical Instruments Stocks With Potential to Outperform
by Zacks Equity Research
Here we discuss ShockWave Medical (SWAV), CheckCap (CHEK) and Biosig Technologies (BSGM) that have the potential to outperform their industry going forward.
Mesa Labs (MLAB) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 18.09% and 6.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of -140.80% and 23.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sensus Healthcare, Inc. (SRTS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 233.33% and 65.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Idexx Laboratories (IDXX) Q1 Earnings Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 0.89% and 0.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sorrento & ViralClear Explore Combination Coronavirus Treatments
by Zacks Equity Research
Sorrento (SRNE) collaborates with ViralClear Pharmaceuticals to evaluate the combination of antibody and antiviral assets against COVID-19.
BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia
by Zacks Equity Research
BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.
BioSig Technologies-Mayo Clinic Ink Electrophysiology Deal
by Zacks Equity Research
This collaboration is expected to bolster BioSig's (BSGM) commitment toward offering higher quality patient care by introducing innovative technological solutions to medicine.
Moving Average Crossover Alert: Biosig Technologies, Inc.
by Zacks Equity Research
Biosig Technologies could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.